JAC Advance Access originally published online on January 14, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 361-365
© 2003 The British Society for Antimicrobial Chemotherapy
Enzymic degradation of a ß-lactam antibiotic, ampicillin, in the gut: a novel treatment modality
1 Faculty of Veterinary Medicine, Department of Clinical Veterinary Sciences, PO Box 57, Helsinki; 2 Institute of Biomedicine/Pharmacology, PO Box 63, University of Helsinki, FIN-00014 Helsinki; 3 Ipsat Therapies Ltd, Sinimäentie 10B, FIN-02630 Espoo, Finland
Received 8 August 2002; returned 29 October 2002; revised 12 November 2002; accepted 20 November 2002
Antibiotics can cause severe alterations in the gut microflora and promote diarrhoea and overgrowth of pathogenic bacteria. The present study investigated the potency of targeted recombinant ß-lactamase (TRBL) to degrade a ß-lactam antibiotic in the jejunum of fistula-operated beagles. We used different peroral doses of purified ß-lactamase (PenP) of Bacillus licheniformis in enteric-coated pellets together with intravenous ampicillin. Serum and jejunal samples were collected for ampicillin and ß-lactamase analysis. A doseresponse effect of TRBL on ampicillin concentrations in the jejunal samples could be observed. The highest doses applied decreased the jejunal ampicillin concentrations to undetectable levels. In the serum samples, the ampicillin concentrations were not affected by the ß-lactamase dose used. Our results indicate that it may be possible to evolve a targeted treatment to degrade ß-lactam antibiotics intestinally and, thus, decrease antibiotic-induced adverse effects on the gut microflora.
Keywords: ß-lactamase, ß-lactams, jejunum, microflora
* Corresponding author. Tel: +358-9-191-49551; Fax: +358-9-191-49670; E-mail: jaana.harmoinen{at}helsinki.fi
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A.-M. Tarkkanen, T. Heinonen, R. Jogi, S. Mentula, M. E. van der Rest, C. J. Donskey, T. Kemppainen, K. Gurbanov, and C. E. Nord P1A Recombinant {beta}-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2455 - 2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Harmoinen, S. Mentula, M. Heikkila, M. van der Rest, P. J. Rajala-Schultz, C. J. Donskey, R. Frias, P. Koski, N. Wickstrand, H. Jousimies-Somer, et al. Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance Antimicrob. Agents Chemother., January 1, 2004; 48(1): 75 - 79. [Abstract] [Full Text] [PDF] |
||||
